TargetBeta
PIK3R5
phosphoinositide-3-kinase regulatory subunit 5 · also P101-PI3K, p101
2 programs in company-led studies act on PIK3R5, from 2 companies: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| gedatolisibrule | Pfizer | phase 3 | 93 running | MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIK3R3 | ChEMBL |
| paxalisibrule | Kazia Therapeutics | phase 2 | 41 running | PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIK3R3 | ChEMBL |
Conditions their studies are in
- Breast Neoplasms, 1 program
- Colorectal Neoplasms, 1 program
- Endometrial Neoplasms, 1 program
- Glioblastoma, 1 program
- Neoplasms, 1 program
- Prostatic Neoplasms, Castration-Resistant, 1 program
- Tuberous Sclerosis, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Feb 2027paxalisib · Kazia Therapeutics · phase 2 · NCT07287202
- Jan 2028gedatolisib · Pfizer · phase 3 · NCT06190899
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.